Detection of donor-specific antibodies in kidney transplantation

British Medical Bulletin

Volumn 110, Issue 1, 2014, Pages 23-34

  Haarberg, Kelley M K ^a   Tambur, Anat R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

C1q; Complement binding antibodies; Donor specific antibodies; HLA antibody epitope; HLA DQ antibodies; Prozone; Solid phase assays

Indexed keywords

COMPLEMENT FIXING ANTIBODY; HLA ANTIBODY; HLA ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; ALLOANTIBODY; COMPLEMENT;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIGENICITY; ARTICLE; COMPLEMENT FIXATION; HLA SYSTEM; HLA TYPING; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; KIDNEY TRANSPLANTATION; PATHOGENICITY; PRIORITY JOURNAL; BLOOD; DONOR; GRAFT REJECTION; IMMUNOASSAY; IMMUNOLOGY; METABOLISM; PROCEDURES; PROGNOSIS;

COMPLEMENT SYSTEM PROTEINS; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOASSAY; ISOANTIBODIES; KIDNEY TRANSPLANTATION; PROGNOSIS; TISSUE DONORS;

EID: 84902009724     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldu005     Document Type: Article

References (64)

1. Kissmeyer-Nielsen F, Olsen S, Petersen VP, et al. Hyperacute rejection of kidney allografts, associated with preexisting humoral antibodies against donor cells. Lancet 1966;2:662-5
2. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969;280:735-9
3. Colvin RB. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007;18:1046-56. (Pubitemid 46536891
4. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donorspecific HLA antibody post kidney transplant. Am J Transplant 2012;12:1157-67
5. Loupy A, Hill GS, Jordan SC. The impact of donorspecific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 2012;8:348-57
6. Otten HG, Verhaar MC, Borst HP, et al. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012;12:1618-23
7. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013;95:19-47
8. Cecka JM, Kucheryavaya AY, Reinsmoen NL, et al. Calculated PRA: Initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant 2011;11:719-24
9. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant 2006;6:2307-15. (Pubitemid 44359415
10. Tambur AR, Ramon DS, Kaufman DB, et al. Perception versus reality?. Virtual crossmatch - how to overcome some of the technical and logistic limitations. Am J Transplant 2009;9:1886-93
11. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011;365:318-26
12. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006;6:346-51. (Pubitemid 43382170
13. Colvin RB, Smith RN. Antibody-mediated organallograft rejection. Nat Rev Immunol 2005;5:807-17
14. Zachary A, Reinsmoen NL. Quantifying HLA-specific antibodies in patients undergoing desensitization. Curr Opin Organ Transplant 2011;16:410-5
15. Taylor CJ, Chapman JR, Ting A, et al. Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Relationship to primary and regraft outcome. Transplantation 1989;48:953-8. (Pubitemid 20018347
16. Haas M, Sis B, Racusen LC, et al., as the Banff meeting report writing committee. Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-Associated arterial lesions. AM J Transplnt 2014;14:272-83
17. Halloran PF, Reeve JP, Pereira AB, et al. Antibodymediated rejection, T cell-mediated rejection, and the injury-repair response: New insights from the Genome Canada studies of kidney transplant biopsies. Kidney Int 2014;85:258-64
18. Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigen-specific antibodies. Hum Immunol 2008;69:591-604
19. Leffell MS, Kim D, Vega RM, et al. Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation. Transplantation 2013
20. Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Contrib Nephrol 2009;162:1-12
21. Susal C, Dohler B, Sadeghi M, et al. HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: A collaborative transplant study report. Transplantation 2009;87:1367-71
22. Susal C, Ovens J, Mahmoud K, et al. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex singleantigen testing: A Collaborative Transplant Study report. Transplantation 2011;91:883-7
23. Tait BD. Solid phase assays for HLA antibody detection in clinical transplantation. Curr Opin Immunol 2009; 21:573-7
24. Zoet YM, Brand-Schaaf SH, Roelen DL, et al. Challenging the golden standard in Defining donor-specific antibodies: Does the solid phase assay meet the expectations?. Tissue Antigens 2011;77:225-8
25. Zachary AA, Vega RM, Lucas DP, et al. HLA antibody detection and characterization by solid phase immunoassays: Methods and pitfalls. Methods Mol Biol 2012;882: 289-308
26. Gebel HM, Liwski RS, Bray RA. Technical aspects of HLA antibody testing. Curr Opin Organ Transplant 2013;18:455-62
27. Reed EF, Rao P, Zhang Z, et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant 2013;13:1859-70
28. Kosmoliaptsis V, Bradley JA, Peacock S, et al. Detection of immunoglobulin G human leukocyte antigen-specific alloantibodies in renal transplant patients using single-Antigen-beads is compromised by the presence of immunoglobulin M human leukocyte antigen-specific alloantibodies. Transplantation 2009;87:813-20
29. Lowe D, Hathaway M, Briggs D. The high-dose hook effect in the detection and monitoring of HLA specific antibody by Luminex assay. Int J Immunogenetics 2007;34:288
30. Zachary AA, Lucas DP, Detrick B, et al. Naturally occurring interference in Luminex assays for HLA-specific antibodies: Characteristics and resolution. Hum Immunol 2009;70:496-501
31. Schnaidt M, Weinstock C, Jurisic M, et al. HLA antibody specification using single-Antigen beads-A technical solution for the prozone effect. Transplantation 2011; 92:510-5
32. Lomago J, Jelenik L, Zern D, et al. How did a patient who types for HLA-B4403 develop antibodies that react with HLA-B 4402?. Hum Immunol 2010;71: 176-8
33. Bohmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: A specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002;13:1091-9. (Pubitemid 34274108
34. Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86:464-70
35. Smith JD, Hamour IM, Banner NR, et al. C4d fixing, luminex binding antibodies - A new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007;7:2809-15. (Pubitemid 350045767
36. Wahrmann M, Bartel G, Exner M, et al. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transpl Int 2009;22:982-9
37. Kushihata F,Watanabe J, Mulder A, et al. Human leukocyte antigen antibodies and human complement activation: Role of IgG subclass, specificity, and cytotoxic potential. Transplantation 2004;78:995-1001. (Pubitemid 39391860
38. Batal I, Zeevi A, Lunz JG 3rd, et al. Antihuman leukocyte antigen-specific antibody strength determined by complement-dependent or solid-phase assays can predict positive donor-specific crossmatches. Arch Pathol Lab Med 2010;134:1534-40
39. Zeevi A, Lunz J, Feingold B, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant 2013;32:98-105
40. Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011;72: 849-58
41. Freitas MC, Rebellato LM, Ozawa M, et al. The role of immunoglobulin-G subclasses and C1q in De novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 2013;95:1113-9
42. Loupy A, Lefaucheur C, Vernerey D, et al. Complementbinding anti-HLA antibodies and kidney-Allograft survival. N Engl J Med 2013;369:1215-26
43. DeVos JM, Gaber AO, Knight RJ, et al. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 2012;82: 598-604
44. Walsh RC, Brailey P, Girnita A, et al. Early and late acute antibody-mediated rejection Differ immunologically and in response to proteasome inhibition. Transplantation 2011;91:1218-26
45. Willicombe M, Brookes P, Sergeant R, et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 2012;94:172-7
46. Barabanova Y, Ramon DS, Tambur AR. Antibodies against HLA-DQ alpha-chain and their role in organ transplantation. Hum Immunol 2009;70:410-2
47. Tambur AR, Leventhal JR, Friedewald JJ, et al. The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation 2010;90:1117-24
48. Tambur AR, Leventhal JR, Walsh RC, et al. HLA-DQ barrier: Effects on cPRA calculations. Transplantation 2013;96:1065-72
49. Tambur AR, Leventhal JR, Zitzner JR, et al. The DQ barrier: Improving organ allocation equity using HLADQ information. Transplantation 2013;95:635-40
50. Parham P, McLean J. Characterization, evolution, and molecular basis of a polymorphic antigenic determinant shared by HLA-A and B products. Hum Immunol 1980;1:131-9. (Pubitemid 12238822
51. Schwartz BD, Luehrman LK, Rodey GE. Public antigenic determinant on a family of HLA-B molecules. J Clin Invest 1979;64:938-47
52. Joysey VC,Wolf E. HLA-A, -B and -C antigens, their serology and cross-reaction. Br Med Bull 1978;34:217-22
53. Brown JH, Jardetzky TS, Gorga JC, et al. Threedimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993;364:33-9. (Pubitemid 23233452
54. Bjorkman PJ, Saper MA, Samraoui B, et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987;329:506-12. (Pubitemid 17131093
55. El-Awar N, Lee JH, Tarsitani C, et al. HLA class I epitopes: Recognition of binding sites by mAbs or eluted alloantibody confirmed with single recombinant antigens. Hum Immunol 2007;68:170-80. (Pubitemid 46356650
56. Duquesnoy RJ. HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. I. Description of the algorithm. HumImmunol 2002;63:339-52
57. Duquesnoy RJ. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol 2006;67:847-62. (Pubitemid 44828199
58. Tambur AR, Claas FH. Toward HLA epitope matching in clinical transplantation. Am J Transplant 2013;13: 3059-60
59. Wiebe C, Pochinco D, Blydt-Hansen TD, et al. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant 2013;13:3114-22
60. Kosmoliaptsis V, Dafforn TR, Chaudhry AN, et al. Highresolution, three-dimensional modeling of human leukocyte antigen class I structure and surface electrostatic potential reveals the molecular basis for alloantibody binding epitopes. Hum Immunol 2011;72:1049-59
61. Kosmoliaptsis V, Bradley JA, Taylor CJ. Structural limitations to the mimetic HLA epitope hypothesis. Transplantation 2009;87:1262-3; author reply 1263
62. Kosmoliaptsis V, Sharples LD, Chaudhry AN, et al. Predicting HLA class II alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation 2011;91:183-90
63. Tambur AR, Rosati J, Roitberg S, et al. Epitope analysis of HLA-DP antigens: What does the antibody see?. (in press), 2014
64. Claas FH, Rahmel A, Doxiadis II. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation 2009;88:447-52